BridgeBio Pharma, Inc. SEC filings BBIO

BridgeBio Pharma, Inc. has 833 filings in SEC EDGAR's recent list, going back to Jun 19, 2018. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 24, 2026 Dec 31, 2025
10-K Annual report Feb 24, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 30, 2025 Dec 31, 2024
10-K Annual report Feb 20, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 25, 2024 Dec 31, 2023
10-K Annual report Feb 22, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 28, 2023 Dec 31, 2022
10-K Annual report Feb 23, 2023 Dec 31, 2022
10-K Annual report Feb 25, 2022 Dec 31, 2021
10-K Annual report Feb 25, 2021 Dec 31, 2020
10-K Annual report Mar 3, 2020 Dec 31, 2019

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BBIO (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Palo Alto, CA
SEC filer status
Large accelerated filer
SEC CIK
1743881
Former names
BridgeBio Pharma LLC (until May 16, 2019)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.